Rapafusyn is a company that appears to specialize in technology solutions. The name suggests a focus on rapid fusion of technology and data to provide innovative services or products.

Rapafusyn Pharmaceuticals is an emerging pharmaceutical development company located in Baltimore Maryland. Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from Johns Hopkins University School of Medicine and seeks to develop novel pharmaceuticals to treat patients having diseases and fulfill unmet medical  needs.

Rapafusyn Pharmaceuticals

Rapafusyn is pleased to announce two presentations at the Drug Discovery Chemistry Meeting, April 1 – 4 in San Diego. Dr. Rick Ewing, VP of Medicinal Chemistry, will be giving an oral presentation on Rapafusyn’s Non-Degradation Molecular Glue platform and Dr. Sam Hong will be presenting a poster on our industry leading libraries of molecular glues. Go to https://lnkd.in/dNkqe6qQ for more details.

Rapafusyn Pharmaceuticals is proud to announce Dr. Rick Ewing, Vice President of Medicinal Chemistry, has been recognized for his outstanding accomplishments with two distinguished awards. Rick has received both the 2023 American Chemical Society (ACS) Philadelphia Section Award, and the 2023 Edison Patent Award in Biotechnology – congratulations Rick! For more information go to https://lnkd.in/eGr94knP


Join us as we share innovative insights, groundbreaking solutions, and a vision for the future! 


Rapafusyn is thrilled to announce two presentations at the upcoming Molecular Glue Drug Discovery Summit, Jan 31 – Feb 1 in Boston. Dr. Rick Ewing, VP of Medicinal Chemistry, will be giving an oral presentation on Rapafusyn’s Non-Degradation Molecular Glue platform and Dr. Matthew Olson will be presenting a poster on our ENT1 program for the treatment of Acute Kidney Injury. Go to https://lnkd.in/dNkqe6qQ for more details.

COM:RAPAFUSYN

Rapafusyn

Analysis Not Available